Positive Phase 2 Study Results Reported for Brigatinib in NSCLC Patients
News
Ariad Pharmaceuticals reported clinical results from its pivotal ALTA Phase 2 trial that evaluated the safety and effectiveness of brigatinib in ALK-positive non-small cell lung cancer (NSCLC) patients whose disease progressed while ... Read more